Market closedNon-fractional
IGM Biosciences/IGMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About IGM Biosciences
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Ticker
IGMS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Mountain View, United States
Employees
216
Website
igmbio.com
IGM Biosciences Metrics
BasicAdvanced
$714M
Market cap
-
P/E ratio
-$4.21
EPS
0.22
Beta
-
Dividend rate
Price and volume
Market cap
$714M
Beta
0.22
Financial strength
Current ratio
7.982
Quick ratio
7.769
Long term debt to equity
21.271
Total debt to equity
25.381
Management effectiveness
Return on assets (TTM)
-37.57%
Return on equity (TTM)
-118.26%
Valuation
Price to revenue (TTM)
323.192
Price to book
4.43
Price to tangible book (TTM)
4.43
Price to free cash flow (TTM)
-3.496
Growth
Revenue change (TTM)
32.31%
Earnings per share change (TTM)
-18.49%
3-year earnings per share growth (CAGR)
11.60%
What the Analysts think about IGM Biosciences
Analyst Ratings
Majority rating from 10 analysts.
IGM Biosciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$400K
-33.33%
Net income
-$50M
-17.82%
Profit margin
-12,450.00%
23.27%
IGM Biosciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.43
-$1.04
-$1.01
-$0.83
-
Expected
-$1.43
-$1.21
-$1.03
-$0.83
-$0.04
Surprise
-0.28%
-14.26%
-2.19%
-0.16%
-
IGM Biosciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IGM Biosciences stock?
IGM Biosciences (IGMS) has a market cap of $714M as of July 27, 2024.
What is the P/E ratio for IGM Biosciences stock?
The price to earnings (P/E) ratio for IGM Biosciences (IGMS) stock is 0 as of July 27, 2024.
Does IGM Biosciences stock pay dividends?
No, IGM Biosciences (IGMS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next IGM Biosciences dividend payment date?
IGM Biosciences (IGMS) stock does not pay dividends to its shareholders.
What is the beta indicator for IGM Biosciences?
IGM Biosciences (IGMS) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell IGM Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.